LumiraDx (LumiraDx) Pre-Tax Income : $-334.23 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. LumiraDx's pretax income for the three months ended in Jun. 2023 was $-49.38 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2023 was $-334.23 Mil. LumiraDx's pretax margin was -235.11%.

During the past 4 years, LumiraDx's highest Pretax Margin was -23.23%. The lowest was -616.41%. And the median was -177.27%.

LumiraDx Pre-Tax Income Historical Data

The historical data trend for LumiraDx's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Pre-Tax Income Chart

LumiraDx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Pre-Tax Income

-142.65

-250.94

-97.91

-443.29

LumiraDx Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Pre-Tax Income	Get a 7-Day Free Trial								-148.13	-141.29	-99.91	-43.64	-49.38

Competitive Comparison of LumiraDx's Pre-Tax Income

For the Diagnostics & Research subindustry, LumiraDx's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LumiraDx's Pre-Tax Income Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, LumiraDx's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where LumiraDx's Pre-Tax Income falls into.

LumiraDx Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

LumiraDx's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-322.624	+	-87.726	+	-43.422	+	10.385	+	0.10200000000003
	=	-443.29

LumiraDx's Pretax Income for the quarter that ended in Jun. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-48.43	+	0	+	-8.091	+	-17.707	+	24.845
	=	-49.38

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-334.23 Mil.

LumiraDx (OTCPK:LMDWF) Pre-Tax Income Explanation

LumiraDx's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-49.383	/	21.004
	=	-235.11%

During the past 4 years, LumiraDx's highest Pretax Margin was -23.23%. The lowest was -616.41%. And the median was -177.27%.

LumiraDx Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of LumiraDx's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

LumiraDx (LumiraDx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDWF) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

LMDXF:USA

Address

C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108

Website

https://www.lumiradx.com

LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.